**University of Dundee**

# RNA-seq analysis of PHD and VHL inhibitors reveals differences and similarities to the hypoxia response

Frost, Julianty; Ciulli, Alessio; Rocha, Sonia

[Link to publication in Discovery Research Portal](Link to publication in Discovery Research Portal)

Check for updates

RESEARCH ARTICLE

# RNA-seq analysis of PHD and VHL inhibitors reveals differences and similarities to the hypoxia response. [version 1; referees: 2 approved]

Julianty Frost (iD)[1], Alessio Ciulli (iD)[2], Sonia Rocha (iD)[1]

[1]Biochemistry-Institute of Integrative Biology, University of Liverpool, Liverpool, L697ZB, UK
[2]Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee, Dundee, DD15EH, UK

## Abstract

**Background:** Hypoxia-inducible factor (HIF) transcription factors are well known to control the transcriptional response to hypoxia. Given the importance of cellular response to hypoxia, a number of pharmacological agents to interfere with this pathway have been developed and entered pre-clinical or clinical trial phases. However, how similar or divergent the transcriptional response elicited by different points of interference in cells is currently unknown.

**Methods:** We performed RNA-sequencing to analyse the similarities and differences of transcriptional response in HeLa cells treated with hypoxia or chemical agents that stabilise HIF by inhibiting components of the hypoxia signalling pathway – prolyl hydroxylase (PHD) inhibitor or von Hippel–Lindau (VHL) inhibitor.

**Results:** This analysis revealed that hypoxia produces the highest changes in gene transcription, with activation and repression of genes being in large numbers. Treatment with the PHD inhibitor IOX2 or the VHL inhibitor VH032 led mostly to gene activation, majorly via a HIF-dependent manner. These results were also confirmed by qRT-PCR using more specific and/or efficient inhibitors, FG-4592 (PHDs) and VH298 (VHL).

**Conclusion:** PHD inhibition and VHL inhibition mimic gene activation promoted by hypoxia via a HIF-dependent manner. However, gene repression is mostly associated with the hypoxia response and not common to the response elicited by inhibitors of the pathway.

## Keywords

Hypoxia, HIF, PHDs, VHL, FG-4592, IOX2, VH298, RNA-seq.

**Open Peer Review**

**Referee Status:** ✔ ✔

|  | Invited Referees | |
| --- | --- | --- |
|  | **1** | **2** |
| **version 1** published 29 Jan 2019 | ✔ report | ✔ report |

1  **James A Nathan** (iD), University of Cambridge, UK

2  **Cormac T. Taylor**, University College Dublin, Ireland

**Discuss this article**

Comments (0)

**Corresponding authors:** Alessio Ciulli (a.ciulli@dundee.ac.uk), Sonia Rocha (srocha@liverpool.ac.uk)

## Introduction

Hypoxia, or reduced oxygen availability, is associated with many physiological processes, such as embryonic development and high altitude living but also pathological processes such as stroke and cancer (Rocha, 2007). A major regulator of oxygen sensing and response is the family of transcription factors called hypoxia-inducible factors (HIFs). HIFs are activated in response to hypoxia to initiate a transcriptional program, and ultimately restore oxygen homeostasis and promote cell survival (Kenneth & Rocha, 2008). HIFs are heterodimeric transcription factors composed of a constitutively stable β-subunit (HIF-1β) and an oxygen-labile α-subunit (HIF-α) (Kenneth & Rocha, 2008). HIF-α is encoded by three different genes: *HIF-1α*, *HIF-2α* and *HIF-3α*, and each could function differently depending on tissue localisation (Kenneth & Rocha, 2008). HIF-α is rapidly degraded by the proteasome under normal oxygen levels as prolyl hydroxylase domain (PHD) enzymes and factor inhibiting HIF (FIH) utilise molecular oxygen as a co-factor, in addition to $Fe^{2+}$ and 2-oxoglutarate, to hydroxylate HIF-α proteins (Kenneth & Rocha, 2008). Hydroxylated prolines on HIF-α create a recognition site with a substantial increase in affinity over the parent protein containing unmodified proline, for the E3 ubiquitin ligase, von Hippel–Lindau (VHL) tumour suppressor that poly-ubiquitinates HIF-α, targeting the protein for proteasomal degradation (Hon *et al.*, 2002). In hypoxia, however, HIF-α evades degradation and is stabilised as a result of insufficient oxygen molecules for PHDs to function. The accumulated HIF-α dimerises with HIF-1β and binds to the consensus motif hypoxia response elements (HREs) of HIF target genes to activate the expression of a wide range of genes associated with key biological processes including metabolism, angiogenesis, cell differentiation, apoptosis and autophagy, for adaptation to hypoxia (Liu *et al.*, 2012).

In addition to the physiological inducer of low oxygen, HIF can be activated by chemical agents that mimic or inhibit components of the hypoxia signalling pathway, including $Fe^{2+}$ substitutes (Wang & Semenza, 1993; Xi *et al.*, 2004), $Fe^{2+}$ chelators (Eltzschig *et al.*, 2014), 2-oxoglutarate mimics (Chan *et al.*, 2016; McDonough *et al.*, 2005), inhibitors of PHDs (Chan *et al.*, 2015; Chowdhury *et al.*, 2013; Locatelli *et al.*, 2017), and more recently, inhibitors of VHL (Buckley *et al.*, 2012; Frost *et al.*, 2016; Galdeano *et al.*, 2014; Soares *et al.*, 2018). Pharmacological stabilisation of HIF could provide therapeutic benefit for many diseases including myocardial ischemia-reperfusion injury (Eckle *et al.*, 2012; Hill *et al.*, 2008; Rey *et al.*, 2009), inflammatory bowel diseases (Biddlestone *et al.*, 2015; Cummins *et al.*, 2013; Marks *et al.*, 2015), anaemia-associated chronic kidney diseases (Macdougall, 2008; Provenzano *et al.*, 2016), wound healing (Albina *et al.*, 2001; Botusan *et al.*, 2008) and assistance of organ transplantation (Cheng *et al.*, 2010). Over the years, PHD inhibitors have entered clinical trials, with FG-4592 in clinical trial phase III for the treatment of anaemia associated with chronic kidney diseases (Provenzano *et al.*, 2016). Recent studies have identified PHD inhibitors or the knockout of *VHL* as protective during mitochondrial dysfunction (Jain *et al.*, 2016). VHL inhibitor VH298 has been demonstrated for the first time *in vivo* to accelerate healing and maturation of enthuses in rats (Qiu *et al.*, 2018), highlighting a therapeutic potential of the inhibitor in wound healing.

Considering the pharmacological use and therapeutic potential of PHD inhibitors and the newly emerging VHL inhibitors, it is important to identify gene expression responses elicited by such agents. As such, we employed RNA-sequencing (RNA-seq) to determine the similarities and differences of the transcriptional response under hypoxia, the inhibitor of PHD, IOX2 (Chowdhury *et al.*, 2013), as well as the VHL inhibitor VH032 (Frost *et al.*, 2016; Galdeano *et al.*, 2014). We show that IOX2 and VH032 mimic the hypoxia response and that these predominantly induce a HIF-dependent gene signature. On the other hand, hypoxia produces the broader transcriptional response amongst all the inducers used, with significant numbers of genes being induced and repressed.

## Methods

### Cell culture

Human cervix carcinoma cells HeLa (ATCC® CCL-2™) and human foreskin fibroblasts HFF (ATCC® SCRC-1041™) were obtained from the American Type Culture Collection (ATCC). All cells were propagated in Dulbecco's Modified Eagle Medium (Sigma; 1992394) supplemented with 10% fetal bovine serum (Gibco; 10082147), 2 mM L-glutamine (Gibco; 25030024), 50 units/mL of penicillin (Lonza) and 50 μg/mL streptomycin (Lonza; DE17-602E) at 37°C. Cells were routinely tested for mycoplasma contamination using MycoAlert kit from Lonza (LT07-218).

### Treatments

For hypoxia induction, cells were incubated at 1% $O_2$ in an InVIVO 300 hypoxia workstation (Ruskin Technologies). To prevent reoxygenation, cells were lysed for protein or RNA extraction in the hypoxia workstation. DMSO was used as vehicle control for compound treatment. PHD inhibitors IOX2 and FG-4592 were purchased from from Sigma (SML0652) or Selleckchem (S2919) and Selleckchem (S1007), respectively. Drugs were added to cells for the indicated length of time. VHL inhibitors VH032 and VH298 were synthesised by Pedro Soares (Ciulli lab, University of Dundee) as previously described: VH032 (ligand 7 in Galdeano *et al.* (2014); compound 1 in (Soares *et al.*, 2018) and VH298 (Frost *et al.*, 2016). VH298 was also purchased from Sigma (SML1896).

### RNA preparation for RNA-seq

HeLa cells were seeded in 35 mm dishes one day prior to treatments with 0.05% DMSO, hypoxia (1% $O_2$), 250 μM IOX2, or 250 μM VH032 for 16 h. RNA was extracted using the RNeasy Mini Kit (Qiagen; 74104) according to manufacturer's instruction. Genomic DNA was removed from RNA samples using RNase-free DNase from Qiagen (79254) as per manufacturer's protocol. Experiments were performed in triplicates.

### RNA-seq library preparation and sequencing

Library preparation and sequencing were performed by the University of Dundee Genome Sequencing Unit. The library was prepared using TruSeq Stranded Total RNA Library Preparation Kit with Ribo-Zero™ Human/Mouse/Rat kit (Illumina; RS-122 2201) to remove ribosomal RNA (rRNA). RNA ERCC ExFold RNA Spike-In Mix (Mix1 and Mix2) was distributed throughout the RNA-seq experiment according to manufacturer's protocol (4456739, Thermo Scientific). Paired-end Illumina sequencing was performed on the NextSeq 500 platform.

## RNA-seq data analysis

The raw sequence reads from each replicate were aligned to the Ensembl human genome GRCh37 and ERCC sequence with STAR version 2.4.2a. The aligned reads were combined and number of reads for each gene was counted with subread-featureCounts pipeline version 1.4.6-p4 (Liao *et al.*, 2014). The files were found to contain ribosomal DNA (rDNA) contaminations, the majority of which were the following two mitochondrial DNA: ENSG00000211459 and ENSG00000210082 – which were removed manually. Differential gene expression analysis was performed by the R package edgeR (v3.24.1) according to its user guide (Robinson *et al.*, 2010), and differentially expressed genes were identified at FDR of <0.05 and log2 fold change > 0.58.

Integrative analysis was performed manually in R (v1.1.453) to obtain lists of genes that overlap to publicly available datasets. Briefly, a list of differentially expressed genes upregulated in hypoxia, IOX2, VH032 or in all three conditions was compared to publicly available data and overlapping genes were exported into excel sheet. Enrichment analysis of transcription factors and chromatin binding proteins on on our datasets was carried out using TFEA.ChIP (v1.2.2) according to its user guide (Puente-Santamaria & Del Peso, 2019). Gene set enrichment analysis was performed using GSEA MSigDB online tool (Liberzon *et al.*, 2011; Subramanian *et al.*, 2005) for hallmark genes with FDR < 0.05 and p value < 0.05.

Sequence data are available from Gene Expression Omnibus GSE120675.

## Quantitative real time-PCR (qRT PCR)

Total RNA extracted using the RNeasy Mini Kit (Qiagen) was reverse transcribed using the iScript™ cDNA Synthesis Kit (BIO RAD; 170-8891). SYBR green-based qRT-PCR was performed in 96-well plate using iQ™ SYBR® green supermix (BIO-RAD; 1708880) in MX3005P qPCR platform (Stratagene/Agilent). Relative quantity or fold change comparing each treatment to DMSO control for the same gene within the replicate (with the exception for *CA9* in which fold changes were calculated comparing to hypoxia) were generated using the MxPro qPCR software (v4.10), based on the ΔΔCT method according to its manual. mRNA level of β-Actin was used for normalisation. Results were shown as mean and SEM of a minimum of three independent experiments. Primers were designed and purchased from Invitrogen. Sequences of primers used are as follows: β-Actin_F, CCCAGAGCAAGAGAGG and β-Actin_R, GTCCAGACGCAGGATG; BNIP3_F, GCCCACCTCGCTCGCA-GACAC and BNIP3_R, CAATCCGATGGCCAGCAAATGAGA; BNIP3L_F, GTGGAAATGCACACCAGCAG and BNIP3L_R, CTTGGGTGGAATGTTTTCGG; CA9_F, CTTTGCCAGAGTT-GACAGG and CA9_R CAGCAACTGCTCATAGGCAC; FAM117B_F, CTCTTGCTGCACCGTATCTT and FAM117B_R, CATGCACTCTCTGTCTGTGTAG;GLUT3_F, CAATGCTCCT-GAGAAGATCAAA and GLUT3_R, AAAGCGGTTGACGAA-GAGT; HK2_F, AGCCCTTTCTCCATCTCCTT and HK2_R, AACCATGACCAAGTGCAGAA; IDH2_F, AGACCGACTTC-GACAAGAATAAG and IDH2_R, GACTGCACATCTCCGT-CATAG; JMJD1A_F, GTCAACTGTGAGGAGATTCCAGC and

JMJD1A_R, AACTTCAACATGAATCAGTGACGG; JMJD2B_F, GGGGAGGAAGATGTGAGTGA and JMJD2B_R, GACG-GCTTTTGGAGGGTAAT; JMJD2C_F, CGAGGTGGAAAGTC-CTCTGAA and JMJD2C_R GGGCTCCTTTAGACTCCATGTAT; JMJD6_F, TGGCATGTTGTCCTCAATCT and JMJD6_R, TCTCCCTCTTACCGTCTTGT; NDRG1_F, GGAGTCCT-TCAACAGTTTGG and NDRG1_R, CACCATCTCAGGGTT-GTTTAG; PHD2_F, GAAAGCCATGGTTGC and PHD2_R, TGTCCTTCTGGAAAAATTCG; PHD3_F, ATCGACAGGCT-GGTCCTCTA and PHD3_R, CTTGGCATCCCAATTCTTGT; RNF187_F, GGGTCTGTGGAAATCATGAGAA and RNF187_R, CAGCTTCTTGTAGTCGGTCAG

## Immunoblotting

Cells were harvested using radio Immunoprecipitation assay (RIPA) lysis buffer (50 mM Tris pH 8, 150 mM NaCl, 0.1% (w/v) SDS, 1% (v/v) NP-40, 0.5% (w/v) sodium deoxycholate, 5 mM NaF, 500 mM $Na_3VO_4$, and one tablet/10 mL Complete, mini, EDTA-free protease inhibitor [Roche; 11873580001]) and kept on ice for 15–30 min before centrifugation at 17,000 × g, 4°C for using Heraeus™ Fresco™ 21 Microcentrifuge (Thermo Scientific) 10 min. The supernatant was collected and stored at –80°C. SDS PAGE and immunoblots were carried out using standard protocols (Frost *et al.*, 2016).

The following primary antibodies were used for immunoblotting (catalogue number, supplier, clonality, host species and dilution factor were included): HIF-1α (610958, BD Biosciences; monoclonal; mouse; 1:1000), β-Actin (66009-1-Ig, Proteintech; monoclonal; mouse; 1:10000), BNIP3 (ab10433, Abcam; monoclonal; mouse; 1:10000), BNIP3L (12396, Cell Signalling; monoclonal; rabbit; 1:1000), CA9 (NB100-417, Novus Biologicals; polyclonal; rabbit; 1:1000), GLUT1 (12939, Cell Signalling; monoclonal; rabbit; 1:1000), GLUT3 (LS-C176045, LSBio; polyclonal; mouse; 1:1000), HK2 (2867S, Cell Signalling; monoclonal; rabbit; 1:2000), JMJD1A (ABE195, Millipore; polyclonal; rabbit; 1:1000), JMJD2B (8639S, Cell Signalling; monoclonal; rabbit; 1:1000), JMJD2C (PA5-23065, Thermo Scientific; polyclonal; rabbit; 1:1000), NDRG1 (5196, Cell Signalling; polyclonal; rabbit; 1:1000), PHD2 (A300-322A, Bethyl Laboratories; polyclonal; rabbit; 1:1000).

## Results

### IOX2 and VH032 induce a similar transcriptional response profile, while hypoxia induces a broader response in cells.

The hypoxia inducible factors (HIFs) can be induced in a variety of different ways, from the physiological inducer of low oxygen, to the pharmacological inhibition of proteins involved in the HIF pathway, as well as by changes in alternative pathways such as transcription and translation (Ferreira *et al.*, 2015; Moniz *et al.*, 2015; Semenza, 2003).

To understand the similarities and differences between the transcriptional responses to several HIF inducers, an unbiased high-throughput RNA-sequencing (RNA-seq) was performed. Human cervical cancer HeLa cells were exposed to 0.05% DMSO (vehicle control), hypoxia (1% $O_2$), PHD inhibitor IOX2 or VHL inhibitor VH032 for 16 hours prior to profiling for global transcriptomic analysis using RNA seq.

Differential expression analysis of data collected from RNA-seq showed that DMSO samples cluster together with weak correlation to the other treatments, whilst hypoxia, IOX2 and VH032 conditions were grouped close to one another (Figure 1A–B). Furthermore, heatmaps generated using the top 100 most differentially expressed (DE) genes in each experimental condition comparing to DMSO control showed that hypoxia (Figure 1C), VH032 (Figure 1D) and IOX2 (Figure 1E) displayed



**Figure 1. Differential gene expression analysis of RNA-seq results.** (**A**) Heatmap of Pearson correlations among RNA-seq samples that have been normalised to their total counts. (**B**) Multidimensional scaling plot of RNA-seq data. The distance between two samples reflects the leading logFC of the corresponding samples. The leading logFC is the average (root mean square) of the 2000 largest absolute logFCs for genes between those two samples. (**C–E**) Heatmaps of log2 counts per million (logcpm) across all the samples using the top 100 most differentially expressed (DE) genes in (**C**) Hypoxia, (**D**) VH032, and (**E**) IOX2. The Pearson correlation was used to compute distances between genes and samples, and the clustering was performed using average linkage. Each column corresponds to a sample and each row corresponds to a specific gene. (**F**) Heatmaps of Pearson correlations between replicates of the same conditions. Each data had been normalised to their total counts. (**G**) Each dot represents a differentially expressed gene comparing the condition stated in the heading legend to DMSO vehicle control. Blue dots represent genes with increased expression (logFC > 0.58; to the right) or decreased expression (logFC < −0.58; to the left) at false discovery rate (FDR)<0.05. Blue triangles (present at −log10 FDR of 30) represent genes with logFC > 0.58 or < −0.58 and −log10 FDR > 30.

similar transcriptional profiles to each other and were notice-ably distinct from the vehicle control DMSO. These observations are likely due to the activation of HIF pathway as the three treatments activate HIF. Correlation analysis heatmaps for each condition showed a strong correlation between 0.95 and 1 across replicates of the same experimental condition (Figure 1F), and replicates of each treatment cluster together in heatmaps of top 100 most DE genes (Figure 1C–E), demonstrating that replicates of each condition were similar and statistically close to each other.

To investigate and observe the differences in gene expression between treatments, volcano plots were generated (Figure 1G). Overall, hypoxia exposure induced the broadest transcriptional changes, followed by IOX2 and finally VH032 resulted in the narrowest profile (Figure 1G). Analysis revealed the presence of more than 2,000 genes that were differentially expressed at 5% false discovery rate (FDR) in hypoxia, with similar numbers of genes being upregulated (1,133; Dataset 1 (Frost, 2019)) and downregulated (957; Dataset 1 (Frost, 2019) (Figure 1G)). Treatments of cells with IOX2 or VH032 induced mostly upregulation of genes (827 in IOX2 and 362 in VH032, Dataset 1 (Frost, 2019)), and only 117 (IOX2; Dataset 1 (Frost, 2019)) and 33 (VH032; Dataset 1 (Frost, 2019)) genes were found to be repressed (Figure 1G).

To investigate the nature of the transcriptional data we obtained, we performed integrative analysis of our hypoxia dataset with publicly available hypoxia-inducible gene sets (Table 1, Dataset 1 (Frost, 2019)). Overlap analysis showed that 36% (410 out the 1,133) genes upregulated in hypoxia were present in at least one of the reported datasets, with 115 genes found upregulated in 16 cell lines (Ortiz-Barahona et al., 2010), 129 genes in HeLa dataset (Mense et al., 2006), as well as 75 and 307 genes in in MCF7 cells (Chan et al., 2016; Elvidge et al., 2006). This analysis confirmed the cell-specific and time-dependent transcriptional responses elicited by hypoxia exposure in cells. We also compared our IOX2 and VH032 datasets with the previously reported gene sets to assess the extent to which genes upregulated in IOX2 or VH032 also hypoxia-inducible. We identified

a large portion of genes upregulated by IOX2 (39%; 325 out of 827) or VH032 (56%; 200 out of 362) to be present in at least one of these reported hypoxia datasets (Table 1, Dataset 1 (Frost, 2019)). This analysis showed that VH032 is predominantly regulating hypoxia-inducible genes, consistent with specific on-target effects on VHL (Frost et al., 2016).

## Genes upregulated in hypoxia, IOX2 and VH032 are HIF-dependent

Comparative analysis of upregulated genes distinctly showed that the majority of VH032-induced genes (~87%; 315 out of 362) are also upregulated by hypoxia (Figure 2A). On the other hand, IOX2-induced genes are only partially shared with the hypoxia signature (~68%; 559 out of 827). Notably, nearly all of the VH032-induced genes (93%) are shared with IOX2. Overall, 306 genes are upregulated in all of the three experimental conditions (Figure 2A; Dataset 1 (Frost, 2019)).

Given that hypoxia, IOX2, and VH032 all induce HIF transcriptional activity, we next investigated the extent to which these 306 overlapped genes upregulated in all three conditions were regulated by HIF transcription factors. We performed integrative analysis on the overlapped genes with reported datasets of validated HIF-1 targets (Benita et al., 2009), as well as HIF-1α and HIF-2α binding sites under hypoxia in MCF7 (Mole et al., 2009) and HepG2 (Smythies et al., 2019) identified in ChIP-sequencing experiments (Table 2, Dataset 1 (Frost, 2019)). This analysis revealed that 132 out of these 306 (43%) genes were HIF-dependent (Table 2, Dataset 1 (Frost, 2019)). A total of 33 out of the 306 shared genes was present in the list of 93 validated HIF-1 target genes (Dataset 1 (Frost, 2019)). Analysis using MCF7 ChIP-seq dataset showed that 62 (20%) and 33 (11%) of the 306 upregulated genes contained HIF-1α and HIF-2α binding sites, respectively (Dataset 1 (Frost, 2019)). A higher level of overlap was observed when we analysed the HepG2 ChIP-seq dataset, revealing that 90 out of the 306 genes (29%) contained either HIF-1α or HIF-2α binding sites (Dataset 1 (Frost, 2019)).

We next utilised TFEA.ChIP that exploits publicly available ChIP-seq datasets to perform enrichment analysis of transcription

**Table 1. Comparison to reported hypoxia-inducible datasets.**

| Description of dataset | Number of genes in the dataset | Number of upregulated genes | | | | Reference |
|---|---|---|---|---|---|---|
| | | Hypoxia (1133) | IOX2 (827) | VH032 (362) | Overlap (306) | |
| Hypoxia-inducible in 16 cell lines | 259 | 115 | 92 | 69 | 64 | (Ortiz-Barahona et al., 2010); Supporting data G |
| HeLa hypoxia-inducible | 1141 | 129 | 100 | 61 | 55 | (Mense et al., 2006); Supporting data H |
| MCF7 hypoxia-inducible_Elvidge2006 | 246 | 75 | 53 | 45 | 42 | (Elvidge et al., 2006); Supporting data I |
| MCF7 hypoxia-inducible_Chan2016 | 1081 | 307 | 257 | 172 | 163 | (Chan et al., 2016); Supporting data J |
| **TOTAL** | | **410** | **326** | **200** | **185** | |

**Figure 2. Analysis of differential expressed genes obtained by RNA-seq.** (**A**) Venn diagrams showing the number of genes upregulated (logFC > 0.58) or downregulated (logFC < –0.58) with false discovery rate (FDR) < 0.05 in hypoxia, IOX2 and VH032 treated cells compared to DMSO control. (**B**) Transcription factor enrichment analysis using TFEA.ChIP showing binding site enrichment for genes commonly upregulated in hypoxia, IOX2 and VH032. The graph represents the adjusted p value (-log10 FDR) and the log-odds ratio (Log2.OR) for the association of ChIP datasets. (**C–D**) Gene set enrichment analysis (GSEA) MsigDB showing significant enrichment of gene set signatures for (**C**) downregulated and upregulated genes in hypoxia, IOX2 or VH032 and (**D**) genes upregulated in hypoxia, IOX2 and VH032 at 5% FDR.

**Table 2. Hypoxia-inducible factors (HIF) dependency analysis.** Our datasets were compared to reported list of validated HIF target genes and ChIP-seq datasets of HIF-1α and HIF-2α binding sites.

| Description of dataset | Number of genes in the dataset | Number of upregulated genes | | | | Reference |
|---|---|---|---|---|---|---|
| | | Hypoxia (1133) | IOX2 (827) | VH032 (362) | Overlap (306) | |
| HIF-1 target | 93 | 49 | 39 | 36 | 33 | (Benita *et al.*, 2009); Supporting data L |
| HIF-1α binding sites (MCF7) | 356 | 101 | 86 | 65 | 62 | (Mole *et al.*, 2009); Supporting data M |
| HIF-2α binding sites (MCF7) | 301 | 65 | 40 | 35 | 33 | (Mole *et al.*, 2009); Supporting data N |
| HIF-1α binding sites (HepG2) | 1516 | 153 | 137 | 94 | 90 | (Smythies *et al.*, 2019); Supporting data O |
| HIF-2α binding sites (HepG2) | 1528 | 173 | 153 | 95 | 90 | (Smythies *et al.*, 2019); Supporting data P |
| **TOTAL** | | **274** | **215** | **141** | **132** | |

factors and chromatin binding proteins on our dataset of commonly upregulated genes (Puente-Santamaria & Del Peso, 2019). Result demonstrated HIF-dependency of the 306 commonly induced genes as HIF transcription factors were significantly enriched. (Figure 2B).

Taken together, these comparative analyses demonstrate the level of HIF dependency for genes upregulated by both hypoxia, IOX2 and VH032.

To investigate the cellular processes induced by hypoxia, IOX2 or VH032, gene set enrichment analysis (GSEA) was performed according to the molecular signature database (MSigDB) (Subramanian *et al.*, 2005; Liberzon *et al.*, 2011). All treatments induced a similar set of enrichment for genes involved in the "cellular response to hypoxia", "glycolysis", "epithelial-mesenchymal transition", "mTORC1 signalling" and "NF-κB signalling" (Figure 2C). However, genes repressed by the different treatments mapped to quite diverse cellular pathways and responses (Figure 2D). Furthermore, the group of 306 commonly upregulated genes in all three conditions was enriched with genes found in these same hallmarks (Figure 2B), primarily hypoxia and glycolysis. Altogether, data indicates that the three treatments activate mainly the hypoxia signalling pathway via HIF transcription factors.

### RNA-seq validation, genes commonly upregulated in hypoxia, IOX2 and VH032

To validate data obtained from the RNA-seq analysis, we selected several known HIF target genes amongst the 306 upregulated genes (*BNIP3*, *BNIP3L*, *CA9*, *GLUT3* [*SLC2A3*], *HK2*, *JMJD1A* [*KDM3A*], *JMJD2B* [*KDM4B*], *JMJD2C* [*KDM4C*], *NDRG1*, *PHD2* [*EGLN1*], and *PHD3* [*EGLN3*]) to perform quantitative real-time PCR (qRT PCR) (Figure 3A). We replaced IOX2 with the PHD inhibitor FG-4592 that is currently in clinical trial phase III (Provenzano *et al.*, 2016). Furthermore, VH032

was replaced with the more potent VHL inhibitor VH298 (Frost *et al.*, 2016). After exposure to 16 hours of hypoxia, FG-4592 (50 μM) or VH298 (100 μM), mRNA levels of these genes increased significantly with similar induction profiles in both HeLa (Figure 3B) and HFF cells (Figure 3C). Hypoxia showed the strongest induction profiles in nearly all genes examined in both cell lines (Figure 3). Moreover, the changes in transcript levels were also reflected at the protein level (Figure 4). Accumulation of the products of these HIF target genes, as well as GLUT1 protein, another HIF target which we had previously characterised at mRNA level (Frost *et al.*, 2016), was detected following 24 hour treatment of hypoxia, VH298 or FG-4592 in HeLa and HFF cells (Figure 4A). In both cell lines, the three treatments induced similar levels of protein expression for the majority of HIF targets assessed, with NDRG1 being the most prominent in hypoxia. FG-4592 was the strongest inducer of CA9 in HeLa cells and BNIP3 in both cell lines (Figure 4A). The difference in the levels these genes and therefore proteins were increased could be due to the single time point used; particularly since the three conditions act on the HIF pathway at different stages (1% oxygen level limits the activities of PHD and FIH, FG 4592 inhibits PHDs and VH298 inhibits VHL downstream of hydroxylation by PHD). To address this question, we performed a time course analysis for the three inducers and investigated protein levels of the different HIF-target genes (Figure 4B). This revealed that hypoxia is the strongest inducer of all the proteins we have analysed at the 24 h post-treatment time point.

### RNA-seq validation, genes solely upregulated in hypoxia and IOX2.

Hypoxia and IOX2 share the larger overlap of 252 upregulated genes that are not found in VH032 (Dataset 1 (Frost, 2019)). On the other hand, there are 30 upregulated common genes between IOX2 and VH032, but not hypoxia, as well as the 9 common upregulated genes in hypoxia and VH032, but not IOX2 (Figure 2A). As recent studies have revealed additional targets of PHD

**Figure 3. Validation of genes with increased transcript level in hypoxia, IOX2 and VH032.** (**A**) Bar plot showing log2FC according to data obtained from RNA seq analysis of known HIF target genes in hypoxia, IOX2 and VH032. (**B**) HeLa and (**C**) HFF cells were treated with 0.05% DMSO (vehicle control), 1% $O_2$ (hypoxia), 100 μM VH298 and 50 μM FG-4592 for 16 h prior to mRNA extraction. The graphs show relative mRNA transcripts normalised to actin mRNA levels. The mean + SEM were determined from three independent experiments. Two-tailed student t-test analysis was performed * $P \leq 0.05$, ** $P \leq 0.01$, *** $P \leq 0.001$ and ns: $P>0.05$.

**Figure 4. Analysis of protein levels of genes with increased transcription in hypoxia, IOX2 and VH032.** HIF targets were increased in hypoxia, VH298 and FG-4592. 0.05% DMSO (vehicle control), 1% $O_2$ (hypoxia), 100 μM VH298 and 50 μM FG-4592 were introduced to (**A**) HeLa or HFF for 24 hours and (**B**) HeLa for indicated time. Protein levels were analysed by immunoblotting using antibodies against indicated proteins, with β-Actin as loading control. The blots shown are representative of three independent experiments. * indicates longer exposure.

enzymes, we analysed several of these 252 genes to determine whether PHDs induce transcriptomic changes independent of HIF activity. We selected four genes, including *IDH2*, *RNF187*, *FAM117B* and *JMJD6* from the list of 252 genes upregulated solely in hypoxia and IOX2 for validation by qRT-PCR. The results, however, show that mRNA levels of these genes increased significantly in all the three conditions, including the VHL inhibitor VH298 (Figure 5A–B). Analysis of the RNA-seq data revealed an increase in each of the four genes in VH032 treatment (Dataset 1 (Frost, 2019)); however, this level was insufficient to reach the threshold of log2FC of 0.58 (Figure 5C). As VH298 is more potent than VH032 (Frost *et al.*, 2016), VH298 is predicted to induce a more pronounced effect on gene expression of target genes. It is likely that the 252 upregulated genes were found to be enriched solely in hypoxia and IOX2, are also induced by the more potent VHL inhibitor VH298, indicative of a common regulator between these treatments. Furthermore, these 252 genes showed significant enrichment of genes involved in pathways similar to commonly upregulated genes (Figure 5D, Figure 2B), as well as enriched for HIF binding sites (Figure 5E).

## Discussion

Here, we used high-throughput RNA-sequencing to investigate the similarity and differences in the transcriptional response towards hypoxia, the PHD inhibitor IOX2 and the VHL inhibitor VH032. Although genome-wide expression profiling comparing hypoxia and IOX2 has previously been reported

(Chan *et al.*, 2016), to our knowledge this is the first report of gene expression profiling comparing side-by-side responses of hypoxia and PHD inhibitors to VHL inhibitors. These three treatments activate the HIF transcription factors, but via limiting or inhibiting different components of the hypoxia signalling pathway.

Our results provide insights into the effects of inhibiting PHD or VHL on HIF target genes, and unique responses in each condition. While hypoxia induced the broadest transcriptional changes, IOX2 and VH032 possessed similar transcriptional responses. The three conditions upregulated a common group of 306 genes (Dataset 1 (Frost, 2019)), the majority of which are regulated by HIF transcription factors (Figure 2B). From this list, we were able to validate a number of known HIF targets in HeLa and HFF cells (Figure 3, Figure 4). Furthermore, we also found that 132 of these 306 genes were either validated HIF targets or possess HIF-1α/2α binding sites (Dataset 1 (Frost, 2019)). This suggest that while the 132 genes are likely HIF targets, the remaining 174 genes (Dataset 1 (Frost, 2019)) could also be potential novel HIF targets.

As hypoxia, VH032 and IOX2 activate HIF, our datasets of genes induced in these conditions are predominantly enriched for HIF transcription factors (Figure 6A–C). Beside gene activation, hypoxia also promotes gene repression. Our results show that hypoxia downregulated a significantly larger number of genes

**Figure 5. RNA seq validation of genes solely upregulated in hypoxia and IOX2, but not VH032.** (**A**) HeLa and (**B**) HFF cells were treated with 0.05% DMSO (vehicle control), 1% O$_2$ (hypoxia), 100 µM VH298 and 50 µM FG-4592 for 16 h prior to mRNA extraction. The graphs show relative mRNA transcripts normalised to actin mRNA levels. The mean + SEM were determined from three independent experiments. Two-tailed student t-test analysis was performed *$P \leq 0.05$, ** $P \leq 0.01$, *** $P \leq 0.001$ and ns: $P>0.05$. (**C**) Table showing log2FC according to data obtained from RNA-seq analysis of known HIF target genes in hypoxia and IOX2, but not VH032. (**D**) Gene set enrichment analysis (GSEA) MsigDB showing significant enrichment of gene set signatures for genes upregulated in hypoxia and IOX2, but not found in VH032 at 5% false discovery rate (FDR). (**E**) Transcription factor enrichment analysis using TFEA.ChIP showing binding site enrichment for genes upregulated in hypoxia and IOX2, but not B032. The graph represents the adjusted p value (-log10 FDR) and the log-odds ratio (Log2.OR) for the association of ChIP datasets.

**Figure 6. Transcription factor enrichment analysis.** Transcription factor enrichment analysis using TFEA.ChIP showing binding site enrichment for genes upregulated in (**A**) VH032, (**B**) IOX2 and (**C**) hypoxia, or (**D**) downregulated in hypoxia. The graph represents the adjusted p-value (-log10 false discovery rate (FDR)) and the log-odds ratio (Log2.OR) for the association of ChIP datasets.

compared to IOX2 and VH032 (Figure 1G). Various mechanisms of transcriptional repression in hypoxia are known (Batie *et al.*, 2018) and one mechanism includes the activity of SIN3A. A recent bioinformatics study showed that SIN3A and a number of its co-repressors including HDAC1 were overrepresented in the proximity of genes transcriptionally repressed by hypoxia (Tiana *et al.*, 2018). Consistent to the reported roles of SIN3A and HDAC1 in hypoxia signalling (Batie *et al.*, 2018), we found that our datasets of downregulated genes in response to hypoxia were enriched for SIN3A and HDAC1 (Figure 6D). The transcription factor REST was also enriched in genes repressed in hypoxia (Figure 6D) and this is consistent to a recent finding that REST transcriptionally repressed genes in hypoxia (Cavadas *et al.*, 2016).

Geneset enrichment analysis suggests that hypoxia, VH032 and IOX2 commonly upregulated genes enriched for NF-κB signalling (Figure 2B). NF-κB is a transcription factor that has been shown to respond to cellular stress, including hypoxia and PHD inhibition (Cummins *et al.*, 2006). Under hypoxia, NF-κB is activated and induces increased angiogenesis and decreased apoptosis (D'Ignazio & Rocha, 2016).

Overall, we reveal for the first time a comparison of genome-wide gene expression analysis of HIF activators, including the physiological inducer hypoxia, and small molecule inhibitors of PHD enzymes and VHL. Understanding the differential regulation of genes in response to the three conditions will help to determine the functions of PHD and VHL in hypoxia

signalling, as well as revealing novel HIF-dependent and –independent genes. Furthermore, considering the potential use of PHD inhibitors that are currently in clinical trials and the potential of VHL inhibitors for therapeutic benefits, our report contributes to the further understanding of the pharmacological effects of these inhibitors.

## Data availability
### Underlying data
Underlying data for this study is available from Open Science Framework (OSF)

OSF: Dataset 1. RNA-seq analysis of PHD and VHL inhibitors reveals differences and similarities to the hypoxia response https://doi.org/10.17605/OSF.IO/4A6TG (Frost, 2019)

Licence: CC0 1.0 Universal

Legend for file Supporting data.xlsx

A – List of genes upregulated in hypoxia with FDR ≤ 5% and logFC ≥ 0.58

B – List of genes downregulated in hypoxia with FDR ≤ 5% and logFC ≤ –0.58

C – List of genes upregulated in IOX2 with FDR ≤ 5% and logFC ≥ 0.58

D – List of genes upregulated in VH032 with FDR ≤ 5% and logFC ≥ 0.58

E – List of genes downregulated in IOX2 with FDR ≤ 5% and logFC ≤ –0.58

F – List of genes downregulated in VH032 with FDR ≤ 5% and logFC ≤ –0.58

G – List of hypoxia-inducible genes conserved across 16 cell lines (Ortiz-Barahona et al., 2010)

H – List of hypoxia-inducible genes in HeLa (Mense et al., 2006)

I – List of hypoxia-inducible genes in MCF7 (Elvidge et al., 2006)

J – List of hypoxia-inducible genes in MCF7 (Chan et al., 2016)

K – List of genes commonly upregulated in hypoxia, IOX2, and VH032. Genes that are found in HIF 1 validated target genes (K), HIF 1α (L) and HIF 2α (M) binding sites in MCF7, as well as HIF 1α (N) and HIF 2α (O) in HepG2 are highlighted in yellow under column C-G, respectively

L – HIF 1 validated target genes (Benita et al., 2009)

M – List of HIF-1α binding sites identified in MCF7 (Mole et al., 2009)

N – List of HIF-2α binding sites identified in MCF7 (Mole et al., 2009)

O – List of HIF-1α binding sites identified in HepG2 (Smythies et al., 2019)

P – List of HIF-2α binding sites identified in HepG2 (Smythies et al., 2019)

Q – List of genes solely upregulated in hypoxia and IOX2, but not in VH032. However, LogFC value in VH032 is stated in column C, together with its p-Value (column D) and FDR (column E)

Sequence data from this study has been uploaded to Gene Expression Omnibus, accession number: GSE120675

## References

Albina JE, Mastrofrancesco B, Vessella JA, et al.: **HIF-1 expression in healing wounds: HIF-1alpha induction in primary inflammatory cells by TNF-alpha.** *Am J Physiol Cell Physiol.* 2001; **281**(6): C1971–7.
**PubMed Abstract** | **Publisher Full Text**

Batie M, Del peso L, Rocha S: **Hypoxia and Chromatin: A Focus on Transcriptional Repression Mechanisms.** *Biomedicines.* 2018; **6**(2): pii: E47.
**PubMed Abstract** | **Publisher Full Text** | **Free Full Text**

Benita Y, Kikuchi H, Smith AD, et al.: **An integrative genomics approach identifies Hypoxia Inducible Factor-1 (HIF-1)-target genes that form the core response to hypoxia.** *Nucleic Acids Res.* 2009; **37**(14): 4587–602.
**PubMed Abstract** | **Publisher Full Text** | **Free Full Text**

Biddlestone J, Bandarra D, Rocha S: **The role of hypoxia in inflammatory disease (review).** *Int J Mol Med.* 2015; **35**(4): 859–69.
**PubMed Abstract** | **Publisher Full Text** | **Free Full Text**

Botusan IR, Sunkari VG, Savu O, et al.: **Stabilization of HIF-1alpha is critical** to improve wound healing in diabetic mice. *Proc Natl Acad Sci U S A.* 2008; **105**(49): 19426–31.
**PubMed Abstract** | **Publisher Full Text** | **Free Full Text**

Buckley DL, Van molle I, Gareiss PC, et al.: **Targeting the von Hippel-Lindau E3 ubiquitin ligase using small molecules to disrupt the VHL/HIF-1α interaction.** *J Am Chem Soc.* 2012; **134**(10): 4465–8.
**PubMed Abstract** | **Publisher Full Text** | **Free Full Text**

Cavadas MA, Mesnieres M, Crifo B, et al.: **REST is a hypoxia-responsive transcriptional repressor.** *Sci Rep.* 2016; **6**: 31355.
**PubMed Abstract** | **Publisher Full Text** | **Free Full Text**

Chan MC, Atasoylu O, Hodson E, et al.: **Potent and Selective Triazole-Based Inhibitors of the Hypoxia-Inducible Factor Prolyl-Hydroxylases with Activity in the Murine Brain.** *PLoS One.* 2015; **10**(7): e0132004.
**PubMed Abstract** | **Publisher Full Text** | **Free Full Text**

Chan MC, Ilott NE, Schödel J, et al.: **Tuning the Transcriptional Response to**

Hypoxia by Inhibiting Hypoxia-inducible Factor (HIF) Prolyl and Asparaginyl Hydroxylases. *J Biol Chem.* 2016; **291**(39): 20661–73.
**PubMed Abstract** | **Publisher Full Text** | **Free Full Text**

Cheng K, Ho K, Stokes R, *et al.*: **Hypoxia-inducible factor-1alpha regulates beta cell function in mouse and human islets.** *J Clin Invest.* 2010; **120**(6): 2171–83.
**PubMed Abstract** | **Publisher Full Text** | **Free Full Text**

Chowdhury R, Candela-lena JI, Chan MC, *et al.*: **Selective small molecule probes for the hypoxia inducible factor (HIF) prolyl hydroxylases.** *ACS Chem Biol.* 2013; **8**(7): 1488–96.
**PubMed Abstract** | **Publisher Full Text**

Cummins EP, Berra E, Comerford KM, *et al.*: **Prolyl hydroxylase-1 negatively regulates IkappaB kinase-beta, giving insight into hypoxia-induced NFkappaB activity.** *Proc Natl Acad Sci U S A.* 2006; **103**(48): 18154–9.
**PubMed Abstract** | **Publisher Full Text** | **Free Full Text**

Cummins EP, Doherty GA, Taylor CT: **Hydroxylases as therapeutic targets in inflammatory bowel disease.** *Lab Invest.* 2013; **93**(4): 378–83.
**PubMed Abstract** | **Publisher Full Text**

D'ignazio L, Rocha S: **Hypoxia Induced NF-κB.** *Cells.* 2016; **5**(1): pii: E10.
**PubMed Abstract** | **Publisher Full Text** | **Free Full Text**

Eckle T, Hartmann K, Bonney S, *et al.*: **Adora2b-elicited *Per2* stabilization promotes a HIF-dependent metabolic switch crucial for myocardial adaptation to ischemia.** *Nat Med.* 2012; **18**(5): 774–82.
**PubMed Abstract** | **Publisher Full Text** | **Free Full Text**

Eltzschig HK, Bratton DL, Colgan SP: **Targeting hypoxia signalling for the treatment of ischaemic and inflammatory diseases.** *Nat Rev Drug Discov.* 2014; **13**(11): 852–69.
**PubMed Abstract** | **Publisher Full Text** | **Free Full Text**

Elvidge GP, Glenny L, Appelhoff RJ, *et al.*: **Concordant regulation of gene expression by hypoxia and 2-oxoglutarate-dependent dioxygenase inhibition: the role of HIF-1alpha, HIF-2alpha, and other pathways.** *J Biol Chem.* 2006; **281**(22): 15215–26.
**PubMed Abstract** | **Publisher Full Text**

Ferreira JV, Soares AR, Ramalho JS, *et al.*: **K63 linked ubiquitin chain formation is a signal for HIF1A degradation by Chaperone-Mediated Autophagy.** *Sci Rep.* 2015; **5**: 10210.
**PubMed Abstract** | **Publisher Full Text** | **Free Full Text**

Frost J: **RNA-seq analysis of PHD and VHL inhibitors reveals differences and similarities to the hypoxia response.** 2019.
**http://www.doi.org/10.17605/OSF.IO/4A6TG**

Frost J, Galdeano C, Soares P, *et al.*: **Potent and selective chemical probe of hypoxic signalling downstream of HIF-α hydroxylation via VHL inhibition.** *Nat Commun.* 2016; **7**: 13312.
**PubMed Abstract** | **Publisher Full Text** | **Free Full Text**

Galdeano C, Gadd MS, Soares P, *et al.*: **Structure-guided design and optimization of small molecules targeting the protein-protein interaction between the von Hippel-Lindau (VHL) E3 ubiquitin ligase and the hypoxia inducible factor (HIF) alpha subunit with *in vitro* nanomolar affinities.** *J Med Chem.* 2014; **57**(20): 8657–63.
**PubMed Abstract** | **Publisher Full Text** | **Free Full Text**

Hill P, Shukla D, Tran MG, *et al.*: **Inhibition of hypoxia inducible factor hydroxylases protects against renal ischemia-reperfusion injury.** *J Am Soc Nephrol.* 2008; **19**(1): 39–46.
**PubMed Abstract** | **Publisher Full Text** | **Free Full Text**

Hon WC, Wilson MI, Harlos K, *et al.*: **Structural basis for the recognition of hydroxyproline in HIF-1 alpha by pVHL.** *Nature.* 2002; **417**(6892): 975–8.
**PubMed Abstract** | **Publisher Full Text**

Jain IH, Zazzeron L, Goli R, *et al.*: **Hypoxia as a therapy for mitochondrial disease.** *Science.* 2016; **352**(6281): 54–61.
**PubMed Abstract** | **Publisher Full Text** | **Free Full Text**

Kenneth NS, Rocha S: **Regulation of gene expression by hypoxia.** *Biochem J.* 2008; **414**(1): 19–29.
**PubMed Abstract** | **Publisher Full Text**

Liao Y, Smyth GK, Shi W: **featureCounts: an efficient general purpose program for assigning sequence reads to genomic features.** *Bioinformatics.* 2014; **30**(7): 923–30.
**PubMed Abstract** | **Publisher Full Text**

Liberzon A, Subramanian A, Pinchback R, *et al.*: **Molecular signatures database (MSigDB) 3.0.** *Bioinformatics.* 2011; **27**(12): 1739–40.
**PubMed Abstract** | **Publisher Full Text** | **Free Full Text**

Liu W, Shen SM, Zhao XY, *et al.*: **Targeted genes and interacting proteins of hypoxia inducible factor-1.** *Int J Biochem Mol Biol.* 2012; **3**(2): 165–78.
**PubMed Abstract** | **Free Full Text**

Locatelli F, Fishbane S, Block GA, *et al.*: **Targeting Hypoxia-Inducible Factors for the Treatment of Anemia in Chronic Kidney Disease Patients.** *Am J Nephrol.* 2017; **45**(3): 187–199.
**PubMed Abstract** | **Publisher Full Text**

Macdougall IC: **Novel erythropoiesis-stimulating agents: a new era in anemia

management.** *Clin J Am Soc Nephrol.* 2008; **3**(1): 200–7.
**PubMed Abstract** | **Publisher Full Text**

Marks E, Goggins BJ, Cardona J, *et al.*: **Oral delivery of prolyl hydroxylase inhibitor: AKB-4924 promotes localized mucosal healing in a mouse model of colitis.** *Inflamm Bowel Dis.* 2015; **21**(2): 267–75.
**PubMed Abstract** | **Publisher Full Text**

Mcdonough MA, Mcneill LA, Tilliet M, *et al.*: **Selective inhibition of factor inhibiting hypoxia-inducible factor.** *J Am Chem Soc.* 2005; **127**(21): 7680–1.
**PubMed Abstract** | **Publisher Full Text**

Mense SM, Sengupta A, Zhou M, *et al.*: **Gene expression profiling reveals the profound upregulation of hypoxia-responsive genes in primary human astrocytes.** *Physiol Genomics.* 2006; **25**(3): 435–49.
**PubMed Abstract** | **Publisher Full Text**

Mole DR, Blancher C, Copley RR, *et al.*: **Genome-wide association of hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha DNA binding with expression profiling of hypoxia-inducible transcripts.** *J Biol Chem.* 2009; **284**(25): 16767–75.
**PubMed Abstract** | **Publisher Full Text** | **Free Full Text**

Moniz S, Bandarra D, Biddlestone J, *et al.*: **Cezanne regulates E2F1-dependent HIF2α expression.** *J Cell Sci.* 2015; **128**(16): 3082–93.
**PubMed Abstract** | **Publisher Full Text** | **Free Full Text**

Ortiz-barahona A, Villar D, Pescador N, *et al.*: **Genome-wide identification of hypoxia-inducible factor binding sites and target genes by a probabilistic model integrating transcription-profiling data and *in silico* binding site prediction.** *Nucleic Acids Res.* 2010; **38**(7): 2332–45.
**PubMed Abstract** | **Publisher Full Text** | **Free Full Text**

Provenzano R, Besarab A, Sun CH, *et al.*: **Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for the Treatment of Anemia in Patients with CKD.** *Clin J Am Soc Nephrol.* 2016; **11**(6): 982–91.
**PubMed Abstract** | **Publisher Full Text** | **Free Full Text**

Puente-Santamaria L, Del Peso L: **ChIP: Analyze Transcription Factor Enrichment.** *bioRxiv.* 2019.

Qiu S, Jia Y, Tang J, *et al.*: **Von Hippel-Lindau (VHL) protein antagonist, VH298, promotes functional activities of tendon-derived stem cells and accelerates healing of entheses in rats by inhibiting ubiquitination of hydroxy-HIF-1α.** *Biochem Biophys Res Commun.* 2018; **505**(4): 1063–1069.
**PubMed Abstract** | **Publisher Full Text**

Rey S, Lee K, Wang CJ, *et al.*: **Synergistic effect of HIF-1alpha gene therapy and HIF-1-activated bone marrow-derived angiogenic cells in a mouse model of limb ischemia.** *Proc Natl Acad Sci U S A.* 2009; **106**(48): 20399–404.
**PubMed Abstract** | **Publisher Full Text** | **Free Full Text**

Robinson MD, Mccarthy DJ, Smyth GK: **edgeR: a Bioconductor package for differential expression analysis of digital gene expression data.** *Bioinformatics.* 2010; **26**(1): 139–40.
**PubMed Abstract** | **Publisher Full Text** | **Free Full Text**

Rocha S: **Gene regulation under low oxygen: holding your breath for transcription.** *Trends Biochem Sci.* 2007; **32**(8): 389–97.
**PubMed Abstract** | **Publisher Full Text**

Semenza GL: **Targeting HIF-1 for cancer therapy.** *Nat Rev Cancer.* 2003; **3**(10): 721–32.
**PubMed Abstract** | **Publisher Full Text**

Smythies JA, Sun M, Masson N, *et al.*: **Inherent DNA-binding specificities of the HIF-1α and HIF-2α transcription factors in chromatin.** *EMBO Rep.* 2019; **20**(1): pii: e46401.
**PubMed Abstract** | **Publisher Full Text** | **Free Full Text**

Soares P, Gadd MS, Frost J, *et al.*: **Group-Based Optimization of Potent and Cell-Active Inhibitors of the von Hippel-Lindau (VHL) E3 Ubiquitin Ligase: Structure-Activity Relationships Leading to the Chemical Probe (2*S*,4*R*)-1-((*S*)-2-(1-Cyanocyclopropanecarboxamido)-3,3-dimethylbutanoyl)-4-hydroxy-*N*-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (VH298).** *J Med Chem.* 2018; **61**(2): 599–618.
**PubMed Abstract** | **Publisher Full Text** | **Free Full Text**

Subramanian A, Tamayo P, Mootha VK, *et al.*: **Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.** *Proc Natl Acad Sci U S A.* 2005; **102**(43): 15545–50.
**PubMed Abstract** | **Publisher Full Text** | **Free Full Text**

Tiana M, Acosta-iborra B, Puente-santamaria L, *et al.*: **The SIN3A histone deacetylase complex is required for a complete transcriptional response to hypoxia.** *Nucleic Acids Res.* 2018; **46**(1): 120–133.
**PubMed Abstract** | **Publisher Full Text** | **Free Full Text**

Wang GL, Semenza GL: **Desferrioxamine induces erythropoietin gene expression and hypoxia-inducible factor 1 DNA-binding activity: implications for models of hypoxia signal transduction.** *Blood.* 1993; **82**(12): 3610–5.
**PubMed Abstract**

Xi L, Taher M, Yin C, *et al.*: **Cobalt chloride induces delayed cardiac preconditioning in mice through selective activation of HIF-1alpha and AP-1 and iNOS signaling.** *Am J Physiol Heart Circ Physiol.* 2004; **287**(6): H2369–75.
**PubMed Abstract** | **Publisher Full Text**

# Open Peer Review

## Current Referee Status:    ✔    ✔

---

**Version 1**

Referee Report 13 February 2019

✔ **Cormac T. Taylor**
UCD Charles Institute of Dermatology, School of Medicine and Medical Science, University College Dublin, Dublin, Ireland

In this manuscript, Frost *et al* have used high-throughput RNA sequencing to compare the cellular transcriptional response to hypoxia with that of pharmacologic HIF hydroxylase or pVHL inhibition. Of interest, hypoxia was a more potent stimulus of gene expression and repression than either hydroxylase or pVHL inhibition. Given the recent introduction of pharmacologic targeting of the HIF hydroxylases into clinical medicine, understanding the cellular consequences of exposure to these agents in terms of global gene expression (while already studied to some degree) is of continuing interest. The manuscript is well written, addresses a clear and interesting hypothesis and delivers clear and important data. The experiments are controlled and appear to be well carried out. The introduction includes a nice up to date review of the pharmacology of the HIF pathway.

**Specific Comments:**

The authors should discuss the choice of IOX2 as a pharmacologic hydroxylase inhibitor for the transcriptomic aspect of the study. What was the rationale of choosing this inhibitor over some of the more commonly used and well characterized agents such as DMOG. Furthermore, the authors should explain why the use of IOX2/VH032 was changed for FG-4592/VH298 for the RT-PCR validation studies (would it not have made more sense to stick with the same compound).

It should be made clear why Hela cells and not a more physiologically relevant cell line were used for the transcriptomic experiments. As these studies involve pharmacologic and hypoxic treatments, could primary cells not have been used? Hela cells carry many chromosomal abnormalities and have limited relevance to normal cell function. This limitation should be discussed.

In Figure 1, it would be good to demonstrate (e.g. by western blot or HRE-liuciferase reporter assay or both) the distinct temporal profile of HIF-1 and HIF-2 expression/activity elicited by the three treatments in Hela cells over the 16 hour time course of exposure. It is possible that these treatments (due to their differential mechanisms) elicit quite different temporal changes in HIF expression which may be of relevance to the genes expressed.

**Is the work clearly and accurately presented and does it cite the current literature?**
Yes

**Is the study design appropriate and is the work technically sound?**
Yes

**Are sufficient details of methods and analysis provided to allow replication by others?**
Yes

**If applicable, is the statistical analysis and its interpretation appropriate?**
Yes

**Are all the source data underlying the results available to ensure full reproducibility?**
Yes

**Are the conclusions drawn adequately supported by the results?**
Yes

*Competing Interests:* CTT is a member of the Scientific Advisory Board of Akebia Therapeutics

*Referee Expertise:* Cellular Physiology, Inflammation, Hypoxia.

**I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.**

Referee Report 11 February 2019

✔  **James A Nathan** (iD)
Department of Medicine, Cambridge Institute for Medical Research, University of Cambridge, Cambridge, UK

Frost et al examine how HIF transcriptional responses vary depending on the mode of HIF activation – hypoxia versus inhibition of HIF-α degradation. Using RNAseq the authors find that hypoxia, PHD inhibition or VHL inhibition activate the same HIF dependent genes but with some differences, principally relating to gene suppression observed in hypoxia. The quality of the data is high and the experiments are well presented. The results substantiate findings in previous reported studies and provide a very useful dataset of hypoxia and/or HIF responsive genes. In addition, they demonstrate a clear difference between the effect of hypoxia on gene repression compared to pharmacological stabilisation of HIF-α. Overall, these findings will be of significant interest to many researchers within the field.

I have only one minor comment regarding the relative stabilisation of HIF-α in response to the different treatments used. The RNAseq analysis was performed on cells treated for 16 hr with 1% oxygen, 250 μM IOX2 or 250 μM VH032. Could the authors comment on the level of HIF-α stabilisation in response to these different treatments? Figure 4B suggests that HIF-1α stabilisation varies over time in a distinct manner with pharmacological inhibition compared to hypoxia. Are similar findings observed for IOX2 and VH032? It would also be helpful if the authors could comment on how HIF-2α may vary following these different treatments.

**Is the work clearly and accurately presented and does it cite the current literature?**

Yes

**Is the study design appropriate and is the work technically sound?**
Yes

**Are sufficient details of methods and analysis provided to allow replication by others?**
Yes

**If applicable, is the statistical analysis and its interpretation appropriate?**
Yes

**Are all the source data underlying the results available to ensure full reproducibility?**
Yes

**Are the conclusions drawn adequately supported by the results?**
Yes

*Competing Interests:* No competing interests were disclosed.

*Referee Expertise:* Hypoxia signalling, metabolism, ubiquitin proteasome system, cell biology, genetics and biochemistry

**I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.**